Three AI accelerator chips illustrating diversification across computing hardware suppliers

Vera Health Raises $28.5M for Its AI Assistant Used by 800,000 Clinicians

ByAIERA Blog Editorial Team

Key Takeaways

  • Vera Health $28.5M Series A, announced on 27 October 2026, was led by Threshold Ventures, with Optum Ventures, Mantis VC, and SV Angel participating.
  • Existing investors Y Combinator and Gradient tripled down in the round, bringing the company’s total funding to $32 million.
  • Vera Health is a clinical AI search engine that searches more than 60 million scientific publications, clinical guidelines, consensus statements, and drug labels before answering.
  • The platform is used by more than 800,000 clinicians in 190 countries, and the company says it grew from a few thousand users a year ago, largely through word of mouth.
  • Every claim Vera gives is linked to its source and colour-coded for evidence strength, so doctors can see what is solid, what is thin, and what is missing.
  • The funding will go toward international growth, locally relevant clinical guidance, and deeper partnerships with medical societies, publishers, and health systems.

Vera Health has raised $28.5 million in Series A funding for a clinical AI search engine that is already used by more than 800,000 clinicians. The announcement, made on 27 October 2026, is notable for two reasons. The first is the scale of adoption: a team of just 12 people has built a tool used by clinicians in 190 countries. The second is the approach: where most AI chatbots generate an answer first and find sources later, Vera searches the evidence first and only then writes the answer. In medicine, that order of operations matters enormously.

The round was led by Threshold Ventures, with participation from Optum Ventures, Mantis VC, and SV Angel. Existing investors Y Combinator and Gradient tripled down, bringing total funding to $32 million. Threshold co-founder and managing partner Emily Melton explained the appeal in a statement, saying Vera is compelling because it starts with the evidence, not just an answer, helping clinicians find and assess the research behind a decision while making its strengths and limitations visible.

A Search Engine That Reasons Like a Clinician

Vera Health describes its platform as a clinical AI search engine that reasons like a clinician. The distinction is worth unpacking. A general-purpose chatbot is trained to produce fluent, confident text. It will answer a medical question in polished sentences, and those sentences may be right, partly right, or wrong, with no visible difference between the three. Vera is built the other way around. It searches more than 60 million scientific publications, clinical guidelines, consensus statements, and drug labels, evaluates the evidence, and then generates an answer with every claim linked to its supporting research.

Each claim is colour-coded to indicate the strength of the available evidence. That matters most when the evidence is weak. A rare condition may have no large randomized trial and no comprehensive guideline behind it. The only available research might be a small case series or a report involving a single patient. A conventional chatbot would either hide that weakness behind confident phrasing or refuse to answer. Vera surfaces the research while making its limitations visible, so the physician can judge how much weight the findings deserve.

Co-founder Taieb Bennani frames the design around four principles: honesty, traceability, transparency, and context. Honesty comes first, in his account, because language models are built to sound certain while medicine rarely is. A general-purpose model produces plausible sentences, but medicine requires verifiable ones. So Vera finds the evidence first and only then writes the answer. That is a small sentence with large implications. It means the system’s value is not in how well it writes, but in how carefully it reads.

The platform is free for licensed clinicians and medical trainees, who can ask questions about diagnoses, medication dosing, guidelines, and treatment, search medical literature, and generate summaries that include links to sources. For health systems, the company offers Vera Spaces, which lets institutions add their own protocols to the platform. The platform is HIPAA-compliant and GDPR-compliant and SOC 2 Type II certified, which are the compliance markers health systems look for before adopting a new tool.

From Two Users to 800,000 Clinicians

The growth story is unusual. Vera Health was co-founded by French entrepreneur and investor Maxime Allouch and Taieb Bennani, and was initially developed for the founders’ fathers, who are both physicians. What began with two users has grown into a platform used by more than 800,000 clinicians worldwide. A year ago, the company says, a few thousand clinicians were using it. Today, most new users discover it through a colleague.

The company reports that every month since June, Vera has been the most downloaded clinical app in the world across the App Store and Google Play, and that in September alone it was downloaded more times than OpenEvidence and Doximity combined, with monthly downloads more than tripled since February. Those download claims come from the company itself, via its announcement, and should be read as company claims rather than independently audited figures. What is independently reported by multiple outlets is the user total of more than 800,000 clinicians and the reach of 190 countries.

The geographic detail is striking. Roughly one in four physicians in Spain and Italy use the platform, according to the company, and about one in seven in France. Growth has run largely on physician referrals, with a team of just 12 employees. Bennani’s explanation is that clinicians check sources, test every answer against what they know, and drop a tool the moment it lets them down. A product that survives that kind of user keeps its users, and those users recruit the next ones.

That dynamic is worth noting for anyone who follows health AI. Most clinical tools grow through institutional sales: long procurement cycles, pilot programs, and committee approvals. Vera grew the other way, clinician by clinician, and only now is raising institutional money to deepen partnerships with medical societies, publishers, and health systems. The Series A is, in that sense, a bet that bottom-up adoption can be converted into institutional relationships, not a bet that adoption will start from scratch.

The 17-Year Gap Vera Is Trying to Close

Bennani cites research in the Journal of the Royal Society of Medicine estimating that new medical knowledge takes about 17 years to reach clinical practice. His company’s mission, as he puts it, is to close the gap between what medicine knows and what every patient receives, and to shrink that gap from years to seconds. The scale of the underlying problem supports the ambition. A new scientific paper is published roughly every 20 seconds, according to the company’s account, which means no clinician can read even a small fraction of the relevant literature.

That is the real job of a clinical AI search engine. It is not to replace the doctor’s judgment. It is to compress the time between a question and the evidence that answers it, and to show the quality of that evidence honestly. A doctor treating a patient with a rare condition does not need a confident paragraph. She needs to know what studies exist, how strong they are, and what they actually say, in seconds rather than hours. If Vera does that reliably, it earns its place at the point of care. If it does not, clinicians will drop it, as Bennani himself acknowledges they do with tools that let them down.

There are limits worth stating plainly. Vera is a decision support tool, not a doctor. Its answers are only as good as the literature it searches, and for many conditions the literature is thin, conflicting, or biased toward certain populations. Colour-coding evidence strength helps, but it does not remove the need for clinical judgment. The platform’s value also depends on keeping its index current across 60 million sources and on tailoring answers to local guidelines, which differ between countries and sometimes between hospitals. The funding will go toward exactly that local relevance: French and European guidance for a doctor in Lyon, for example, versus a different framework for a doctor in Chicago.

Readers interested in how AI handles medical information should also see our article on AI scribe errors in healthcare and what actually goes wrong in 2026, which looks at the failure modes of clinical AI from the other side. And for a different kind of biology AI, our piece on Hugging Face Carbon-X, the model that lets you chat with DNA shows how AI is opening up genetic data to non-specialists. Vera belongs to the same broader story: AI tools that make specialist knowledge accessible, with the evidence attached.

What the Funding Will Do

The company says the Series A will accelerate its evidence-focused platform, expand its ability to make global medical knowledge locally relevant, and deepen partnerships with medical societies, publishers, and health systems. It will also continue investing in locally relevant clinical guidance and tools that let healthcare institutions incorporate their own medical knowledge into the platform.

That local-first approach is the strategic core. Medical guidance is not universal. Treatment protocols, drug availability, and regulatory rules vary by country, and a tool that gives an American answer to a French doctor is worse than useless. Vera’s plan is to tailor answers to national guidelines and language, and to let health systems add their own protocols through Vera Spaces. If it executes that well, it becomes infrastructure for clinical decision-making rather than just another app. If it executes it poorly, it becomes a generic search tool with a medical label.

The investor mix supports that reading. Threshold Ventures led the round. Optum Ventures, the healthcare venture firm backed by UnitedHealth Group, brings health system relationships. Y Combinator and Gradient, both existing investors, tripled their backing. That combination of a generalist lead, a healthcare specialist, and committed early backers suggests the company is being funded to scale an already working product, not to find one.

The honest summary is this. Vera Health has built a clinical AI tool that hundreds of thousands of doctors use voluntarily, which is a rare achievement in healthcare. It has now raised $28.5 million to turn that adoption into institutional partnerships and locally relevant guidance. The open questions are the ones that matter for every health AI company: whether the evidence engine stays reliable as it scales, whether local guidance keeps pace with global growth, and whether clinicians keep trusting a tool that must sometimes tell them the evidence is thin. Those questions will be answered by usage, not by funding announcements, and the next year of Vera’s growth will be worth watching closely.

Sources

Similar Posts